D-Index & Metrics Best Publications
Research.com 2022 Rising Star of Science Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 97 Citations 65,167 326 World Ranking 4376 National Ranking 2471
Rising Stars D-index 97 Citations 66,176 343 World Ranking 2 National Ranking 1

Research.com Recognitions

Awards & Achievements

2022 - Research.com Rising Star of Science Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

Internal medicine, Lung cancer, Oncology, Cancer and Immunotherapy are his primary areas of study. Matthew D. Hellmann studies Nivolumab which is a part of Internal medicine. His Lung cancer study incorporates themes from Pembrolizumab, Clinical trial, Survival rate, Surgery and Carcinoma.

In the subject of general Pembrolizumab, his work in Atezolizumab is often linked to Monoclonal, thereby combining diverse domains of study. His work deals with themes such as Blockade, Antibiotics, Immune system and Pathology, which intersect with Cancer. In his work, Checkpoint Blockade Immunotherapy is strongly intertwined with Melanoma, which is a subfield of Immunotherapy.

His most cited work include:

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (4293 citations)
  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer (4293 citations)
  • Pembrolizumab for the treatment of non-small cell lung cancer (3324 citations)

What are the main themes of his work throughout his whole career to date?

Matthew D. Hellmann mainly investigates Internal medicine, Oncology, Lung cancer, Cancer research and Immunotherapy. His is doing research in Nivolumab, Cancer, Chemotherapy, Pembrolizumab and Lung, both of which are found in Internal medicine. His biological study spans a wide range of topics, including Blockade and Clinical trial.

Matthew D. Hellmann has included themes like Survival rate, Adverse effect, KRAS, Carcinoma and Biomarker in his Lung cancer study. His work in Cancer research covers topics such as T cell which are related to areas like CD8. His Immunotherapy research is multidisciplinary, incorporating perspectives in Melanoma and Retrospective cohort study, Pathology.

He most often published in these fields:

  • Internal medicine (73.97%)
  • Oncology (62.19%)
  • Lung cancer (43.56%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (73.97%)
  • Oncology (62.19%)
  • Lung cancer (43.56%)

In recent papers he was focusing on the following fields of study:

Matthew D. Hellmann mainly focuses on Internal medicine, Oncology, Lung cancer, Immunotherapy and Cancer. His Lung, Blockade, Adverse effect and Durvalumab study in the realm of Internal medicine interacts with subjects such as In patient. The study incorporates disciplines such as Stage, Nivolumab, Ipilimumab and Clinical trial in addition to Oncology.

His Lung cancer study which covers KRAS that intersects with Tumor progression. His research in Immunotherapy intersects with topics in Biomarker, Cancer research and CD8. His study in the fields of Cancer immunotherapy under the domain of Cancer overlaps with other disciplines such as Pandemic.

Between 2019 and 2021, his most popular works were:

  • Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. (100 citations)
  • Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. (100 citations)
  • Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort (57 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His main research concerns Lung cancer, Internal medicine, Immunotherapy, Oncology and Cancer. His research on Lung cancer concerns the broader Pathology. His studies in Immunotherapy integrate themes in fields like Pharmacokinetics, Lesion and Cancer research, Melanoma.

His studies deal with areas such as Blockade, Nivolumab, Ipilimumab and Circulating tumor DNA as well as Oncology. His work deals with themes such as Precision medicine, Clinical trial and Gene mutation, which intersect with Cancer. Matthew D. Hellmann has researched Immune checkpoint in several fields, including Cell, CD8 and Long term response.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg.
Science (2015)

5352 Citations

Pembrolizumab for the treatment of non-small cell lung cancer

Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl.
The New England Journal of Medicine (2015)

4445 Citations

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov.
Science (2016)

1822 Citations

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee.
The New England Journal of Medicine (2018)

1661 Citations

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed.
Nature Medicine (2017)

1571 Citations

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Michael A Postow;Robert Sidlow;Matthew D Hellmann.
The New England Journal of Medicine (2018)

1500 Citations

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong.
Science (2018)

1404 Citations

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel.
Journal of Clinical Oncology (2015)

1052 Citations

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann.
Nature Genetics (2019)

999 Citations

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila.
Journal of Clinical Oncology (2018)

815 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Matthew D. Hellmann

David B. Solit

David B. Solit

Memorial Sloan Kettering Cancer Center

Publications: 108

Michael F. Berger

Michael F. Berger

Memorial Sloan Kettering Cancer Center

Publications: 105

Charles Swanton

Charles Swanton

The Francis Crick Institute

Publications: 100

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 100

David M. Hyman

David M. Hyman

Loxo Oncology

Publications: 100

Eliezer M. Van Allen

Eliezer M. Van Allen

Harvard University

Publications: 91

Douglas B. Johnson

Douglas B. Johnson

Vanderbilt University Medical Center

Publications: 83

Marc Ladanyi

Marc Ladanyi

Memorial Sloan Kettering Cancer Center

Publications: 76

Jedd D. Wolchok

Jedd D. Wolchok

Memorial Sloan Kettering Cancer Center

Publications: 75

Caicun Zhou

Caicun Zhou

Tongji University

Publications: 74

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 73

Aurélien Marabelle

Aurélien Marabelle

Institut Gustave Roussy

Publications: 70

John V. Heymach

John V. Heymach

The University of Texas MD Anderson Cancer Center

Publications: 69

F. Stephen Hodi

F. Stephen Hodi

Harvard University

Publications: 68

Alexander Drilon

Alexander Drilon

Memorial Sloan Kettering Cancer Center

Publications: 64

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 64

Something went wrong. Please try again later.